Global Pneumococcal Vaccines Market is valued at USD 8.49 Billion in 2021 and expected to reach USD 12.11 Billion by 2028 with a CAGR of 5.2% over the forecast period.
Global Pneumococcal Vaccines Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2022-2028- Increasing prevalence of pneumonia, rising technological advancements in this field and a growing number of government initiatives regarding the awareness about vaccination are major factors anticipated to drive the growth of the Global Pneumococcal Vaccines Market.
Pneumonia is serious life-threatening disease also can cause an ear infection. Some of the major symptoms of Pneumococcal disease are shortness of breath, cough, chest pain and it can be spread from person to person through coughing and sneezing. It is caused by streptococcus pneumonia bacteria. Pneumonia causes serious lung infection which results into swelling of air sacs in one or both the lungs. The air sacs get filled with liquid or pus resulting in chills, fever, cough and breathing complexity. The pneumococcal vaccines are given for protecting against pneumococcal disease. Pneumonia vaccines are of two type’s conjugates vaccines and polysaccharide vaccines. The conjugate vaccine is given to all children’s younger than 2 years and polysaccharide vaccine is given to adults of 65 years or older than 65 whom are smokers. The pneumococcal conjugate vaccine (PCV13) and the pneumococcal polysaccharide vaccine (PPSV23) secure against pneumococcal diseases. The pneumococcal vaccines are best preventive measure against pneumococcal disease. The primary pneumococcal vaccine was authorized for use in the United States in 1977. The main conjugate pneumococcal vaccine was authorized in the United States in 2000.
The Covid-19 pandemic has shown a positive impact on the global pneumococcal vaccines market because the Covid-19 infection results into for pneumococcal illness. The severe Covid infection can lead to pneumonia. The people having a history of pneumonia have an increased risk of death from Covid-19. Hence, demand for pneumococcal vaccination was increased during the Covid-19 pandemic. However, due to lockdown and supply chain disruptions the vaccine production shown a decline.
The global pneumococcal vaccines market is segmented into on the basis of type, indication, product, distribution channel and region & country level. On the basis of type, the global pneumococcal vaccines market is classified into conjugate vaccines and polysaccharide vaccines. On the basis of indication, the pneumococcal vaccine market was divided into bronchitis, meningitis, pneumonia, and sepsis. On the basis of product, the pneumococcal vaccine market was segmented into pneumovax23, Prevnar 13 and Synflorix. On the basis of distribution channel, the pneumococcal vaccine market is classified into government authorities and non-governmental organizations.
Some of the key players for global pneumococcal vaccines market are
News: ADDING and REPLACING European Commission Approved Merck’s VAXNEUVANCE (Pneumococcal 15-valent Conjugate Vaccine) for Individuals 18 Years of Age and Older
On December 15th, 2021; Merck declared the European Commission (EC) approved VAXNEUVANCE (Pneumococcal 15-valent Conjugate Vaccine) for dynamic inoculation for the prevention of obtrusive illness and pneumonia brought about by Streptococcus pneumonia in people 18 years old and older. The endorsement permits advertising of VAXNEUVANCE in every one of the 27 European Union (EU) Member States in addition to Norway, Iceland and Lichtenstein. The utilization of VAXNEUVANCE in the EU should be as per official suggestions.
The First and Only Indigenous Pneumonia Vaccine Launched By Serum Institute of India
On December 28th, 2020; the first pneumococcal vaccine launched by The Serum Institute of India. The named the pneumococcal conjugate vaccine and it was India’s first made-in-India vaccine to protect children against the pneumonia disease in India. The vaccine was cost-effective. The vaccine will benefit not only the children of India, but with the help of UNICEF and other health agencies, children from all over the world stated.
Increasing Prevalence of Pneumonia, Rising Technological Advancements and Growing Number of Government Initiatives regarding the Awareness are Driving the Market Growth
One of the major factors driving the growth of the global pneumococcal vaccines market is increasing prevalence of pneumonia. The Streptococcus pneumonia is the foremost cause of pneumonia mortality worldwide. Increasing cases of pneumonia increases the demand for vaccine to avoid the diseases. For example; according to World Health Organization (WHO), pneumonia kills half a million children under 5 years old worldwide every year. In addition, another major factor for the growth of global pneumococcal vaccines market is raising technological advancements in vaccine development. The pneumonia is life threatening disease and can be prevented through vaccinations. The biopharmaceuticals are continuously working and making the technological advanced vaccine. Also, during pandemic, the need for pneumococcal vaccinations is increased as the Covid infection can led to severe pneumonia. For example; as per the news published on December 16th, 2021, the Merck’s pneumonia vaccine was approved by European Commission (EC) EC for use in adults. Merck’s (MSD) pneumococcal 15-valent is a conjugate vaccine, Vaxneuvance, to prevent invasive disease and pneumonia in adults aged 18 years and above.
Furthermore, growing number of supportive government initiatives regarding the awareness about vaccination are also fostering the growth of the global pneumococcal vaccines market. Various programmes for increasing awareness and free availability of the vaccine also drive the market growth. For instance; as per the news published on October 29th, 2021, expansion of Pneumococcal 13-valent Conjugate Vaccine (PCV) under the Universal Immunization Programme (UIP) was launched health minister, in India. With help of this programme, they aimed to create awareness in the children’s and immunization.
However, high cost for the development of pneumococcal vaccines and longer timeline needs for pneumonia vaccine production may hamper the growth of global pneumococcal vaccines market. In spite of that, rising awareness regarding vaccines and development of protein-based combination pneumococcal vaccines can provide various opportunities for the further growth of the global pneumococcal vaccines market.
North America is expected to dominate the global pneumococcal vaccines market due to increasing number of pneumococcal infections, the presence of key players and highly developed healthcare infrastructure. For instance, according to the Center for Disease Control (CDC); pneumococcal bacteria caused more than 4,800 cases of invasive pneumococcal disease every year in United States. In addition to that, approval by F.D.A is also supplementing the market growth in this region. For example; as per the news published on June 8th, 2021, FDA permitted PREVNAR 20, Pfizer’s Pneumococcal 20-valent Conjugate Vaccine for grown-ups and one more vaccine called Vaxneuvance approved by FDA in July 2021, for adults to prevent against invasive pneumococcal disease 18. Furthermore, research and development in U.S and helpful government initiatives expected to boost the market in North America.
The Asia Pacific is the fastest-growing region in the global pneumococcal vaccines market due to the increasing number of pneumococcal diseases, government programmes for awareness of vaccines and rising number of R & D activities in this field. For example; according to the NCBI; Streptococcus pneumonia causes 0.7-1 million deaths in children every year, in India.
Middle East and Africa
|2015 - 2020
|2021 - 2028
|Market Size in 2021:
|USD 8.49 Billion
|Base year considered
|Forecast Period CAGR %:
|Market Size Expected in 2028:
|USD 12.11 Billion
|Tables, Charts & Figures:
|Pneumococcal Vaccine Manufacturers
|Astellas Pharma Inc., Pfizer Inc., AstraZeneca PLC, CSL Limited, Emergent BioSolutions Inc., GlaxoSmithKline PLC, Merck & Co., Inc., Pnuvax Incorporated, Johnson & Johnson, Sanofi S.A., Serum Institute of India Pvt. Ltd., others.
|By Type, By Indication, By Product, By Distribution channel
|North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us firstname.lastname@example.orgJOIN US
BrandEssence® Market Research and Consulting Pvt ltd.
124, City Road, London EC1V 2NX
© Copyright 2024-25 BrandEssence® Market Research and Consulting Pvt ltd. All Rights Reserved | Designed by BrandEssence®